- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03528096
Vestibular Stimulation Therapy for Rhythmic Movement Disorder
Feasibility Study of Contactless 3D Video Assessment and 'Somnomat' Vestibular Stimulation Therapy in Childhood Rhythmic Movement Disorder
Study Overview
Status
Intervention / Treatment
Detailed Description
Rhythmic movement disorder (RMD) is a childhood onset sleep disorder that is characterised by repetitive movements that involve large muscle groups, such as body rocking, rolling and head banging. These rhythmic movements are performed prior to and during sleep and as such can disturb sleep with clinical consequences. There is no standard measure to quantify the severity of rhythmic movements. 3D video offers a contactless method of achieving this without disrupting the child's sleep. Vestibular stimulation has a soothing effect and might be effective in promoting sleep. Furthermore, mild vestibular stimulation in the form of gentle rocking movements generated by the Somnomat device might function as a stimulation substitute for the child's RMD with therapeutic potential.
This study aims to a) investigate the feasibility of the detection of episodes of RMD using contactless 3D video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zurich
-
Zürich, Zurich, Switzerland, 8092
- Sensory Motor Systems Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- RMD diagnosis based on ICSD III criteria or RMD suspected
- Typically developing
- Child and accompanying adult are legally allowed to enter Switzerland without a visa
- Both child and parent/legal guardian understand easy English or German
Exclusion Criteria:
- Moderate or severe learning disability
- Neurological disorder (incl. autism, epilepsy, medicinally treated ADHD)
- Currently using medication that influences sleep
- Known diseases of the vestibular system
- Self-reported sensitivity for motion sickness
- Body height > 1.95 m (due to the constraints of the setup)
- Body weight > 130 kg (due to the constraints of the setup)
- Flu, cold or other acute disease on study day that might influence measurements
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention night
Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed.
Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms.
The stimulation frequency is in the range of 0.25-2 Hz.
|
Vestibular stimulation is provided using an innervated bed platform.
This robotic device consists of a standard single bed, mounted on a moving mechanism.
It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
|
Sham Comparator: Baseline night
The sound of the moving bed is played back to the participant at the right sound intensity level.
|
Sound of the moving bed was recorded and played back during the baseline night.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Therapy on Subjective Sleep Quality
Time Frame: 2 nights
|
Difference in perceived sleep quality between baseline and intervention nights.
Data is collected in the first hour after awakening using a questionnaire.
|
2 nights
|
Reliability of Automatic Detection of Symptoms
Time Frame: 3 nights
|
Episodes of rhythmic movement scored by an algorithm using 3D Video will be compared to the scoring of an expert
|
3 nights
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Therapy on Objective Sleep Quality
Time Frame: 2 nights
|
Sleep quality is determined based on 2D video recordings and compared between baseline and intervention nights.
|
2 nights
|
Effect of Therapy on Symptoms
Time Frame: 2 nights
|
Severity of symptoms is determined based on 2D video recordings.
The number of episodes of rhytmic movement (count) and the duration of episodes (minutes) compared between baseline and intervention nights.
|
2 nights
|
Preferred Stimulation Parameters
Time Frame: 1.5 hours
|
Participants can try out different directions of movement (pitch or roll) and different movement frequencies between 0 and 2 Hz and choose their preferred settings (one direction + one frequency).
|
1.5 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert Riener, Prof. Dr., ETH Zurich
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMD-SOMNOMAT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Related Rhythmic Movement Disorder (Disorder)
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Massachusetts General HospitalRecruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Mayo ClinicEnrolling by invitationSleep Disorder | Restless Legs Syndrome | Iron-deficiency | Periodic Limb Movement Sleep DisorderUnited States
-
Ruijin HospitalWuhan Union Hospital, China; Second Affiliated Hospital of Soochow UniversityRecruitingRapid Eye Movement Sleep Behavior Disorder | SynucleinopathyChina
-
HealthRhythms, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...CompletedSleep Disorder | Sleep Disturbance | Alcohol Use Disorder (AUD) | Alcohol Abuse With Alcohol-Induced Sleep DisorderUnited States
-
Mayo ClinicRecruitingParkinson Disease | Rapid Eye Movement Sleep Behavior DisorderUnited States
-
CuraSen Therapeutics, Inc.Active, not recruitingMild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease DementiaAustralia, New Zealand, United Kingdom
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
-
University Hospital, Clermont-FerrandNot yet recruitingSleep Disorder | Post Traumatic Stress DisorderFrance
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
Clinical Trials on Somnomat B
-
Swiss Federal Institute of TechnologyUniversity of ZurichCompleted
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationActive, not recruitingHIV Infection | Hepatitis BUnited States, Haiti, Botswana, Philippines, Thailand, Brazil, Kenya, Malawi, India, South Africa, Uganda, Vietnam
-
Indiana UniversityAlcon ResearchCompleted
-
ChemoCentryxMedpace, Inc.CompletedFocal Segmental Glomerulosclerosis | FSGS | GlomerulosclerosisUnited States, France, Italy, Australia, United Kingdom, Canada, New Zealand, Poland
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
Marya Strand, MDCompletedRespiratory Distress SyndromeUnited States
-
Soroka University Medical CenterCompletedInflammatory Bowel DiseaseIsrael
-
Epstein, Arthur B., OD, FAAOAlcon ResearchCompleted
-
Wright State UniversityRecruiting